心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2019 阿司匹林在心血管疾病一级预防中的应用中国专家共识

2019-08-19 中国心血管相关专家小组（统称） 中华心血管病杂志( 网络版),2019,2:e1-e5

阿司匹林心血管疾病一级预防

《2019 阿司匹林在心血管疾病一级预防中的应用中国专家共识》基于近期发表的阿司匹林在心血管疾病一级预防的多项随机对照研究和荟萃分析，参照我国相关指南和共识，结合我国国情，对阿司匹林在心血管疾病一级预防中更加精准的适用人群、不适宜人群及相关的其他问题等给予了明确和实用的推荐，对我国心血管疾病的一级预防具有重要的指导意义。

中文标题：

2019 阿司匹林在心血管疾病一级预防中的应用中国专家共识

发布机构：

中国心血管相关专家小组（统称）

发布日期：

2019-08-19

简要介绍：

《2019 阿司匹林在心血管疾病一级预防中的应用中国专家共识》基于近期发表的阿司匹林在心血管疾病一级预防的多项随机对照研究和荟萃分析，参照我国相关指南和共识，结合我国国情，对阿司匹林在心血管疾病一级预防中更加精准的适用人群、不适宜人群及相关的其他问题等给予了明确和实用的推荐，对我国心血管疾病的一级预防具有重要的指导意义。

 

拓展指南：与阿司匹林相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2019 阿司匹林在心血管疾病一级预防中的应用中国专家共识)] GetToolGuiderByIdResponse(projectId=1, id=7a2ab1c001e8231a, title=2019 阿司匹林在心血管疾病一级预防中的应用中国专家共识, enTitle=, guiderFrom=中华心血管病杂志( 网络版),2019,2:e1-e5, authorId=null, author=, summary=《2019 阿司匹林在心血管疾病一级预防中的应用中国专家共识》基于近期发表的阿司匹林在心血管疾病一级预防的多项随机对照研究和荟萃分析，参照我国相关指南和共识，结合我国国情，对阿司匹林在心血管疾病一级预防中更加精准的适用人群、不适宜人群及相关的其他问题等给予了明确和实用的推荐，对我国心血管疾病的一级预防具有重要的指导意义。 , cover=, journalId=null, articlesId=null, associationId=306, associationName=中国心血管相关专家小组（统称）, associationIntro=本制定者非特指某个专家小组，为统称。, copyright=0, guiderPublishedTime=Mon Aug 19 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>《2019 阿司匹林在心血管疾病一级预防中的应用中国专家共识》基于近期发表的阿司匹林在心血管疾病一级预防的多项随机对照研究和荟萃分析，参照我国相关指南和共识，结合我国国情，对阿司匹林在心血管疾病一级预防中更加精准的适用人群、不适宜人群及相关的其他问题等给予了明确和实用的推荐，对我国心血管疾病的一级预防具有重要的指导意义。 </P> <P> </P>拓展指南：<strong>与<font color=red>阿司匹林</font>相关指南：</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=bc4e71c00169eaf6" title="2018 临床实践指南：急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗" target=_blank>2018 临床实践指南：急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=8792e1c001ae80b5" title="阿司匹林在动脉粥样硬化性心血管疾病中的临床应用：中国专家共识（2016）" target=_blank>阿司匹林在动脉粥样硬化性心血管疾病中的临床应用：中国专家共识（2016）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=1a9631c001281844" title="2015 阿司匹林用于心血管疾病一级预防的专家建议" target=_blank>2015 阿司匹林用于心血管疾病一级预防的专家建议</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=c8ae31c0012a5851" title="2016 ESC意见书：非阿司匹林非甾体抗炎药物的心血管安全性" target=_blank>2016 ESC意见书：非阿司匹林非甾体抗炎药物的心血管安全性</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=e7e2c1c00122e116" title="2016 USPSTF建议声明：阿司匹林用于心血管疾病和结直肠癌的一级预防" target=_blank>2016 USPSTF建议声明：阿司匹林用于心血管疾病和结直肠癌的一级预防</a></li> 更多信息请点击：<a href="https://www.medsci.cn/guideline/list.do?q=%E9%98%BF%E5%8F%B8%E5%8C%B9%E6%9E%97" target=_blank>有关阿司匹林更多指南</a></ul>, tagList=[TagDto(tagId=659, tagName=阿司匹林), TagDto(tagId=2529, tagName=心血管疾病), TagDto(tagId=2930, tagName=一级预防)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10717, appHits=1102, showAppHits=3, pcHits=4104, showPcHits=6994, likes=124, shares=50, comments=18, approvalStatus=1, publishedTime=Tue Aug 20 22:19:14 CST 2019, publishedTimeString=2019-08-19, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Aug 20 22:19:14 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 14:21:52 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 阿司匹林在心血管疾病一级预防中的应用中国专家共识)])
2019 阿司匹林在心血管疾病一级预防中的应用中国专家共识
下载请点击：
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1180624, encodeId=1a10118062486, content=学习后获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d945605913, createdName=ms7000001100972409, createdTime=Tue Jan 04 23:01:47 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077673, encodeId=57b910e7673f6, content=不错，认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7295648313, createdName=ms6000001488748724, createdTime=Tue Dec 07 10:01:01 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058031, encodeId=f272105803181, content=很方便, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ace5622459, createdName=ms3000001281480633, createdTime=Wed Oct 06 08:17:07 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011063, encodeId=a22210110634a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b594200092, createdName=13d7108bm77暂无昵称, createdTime=Tue Aug 24 18:05:51 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010197, encodeId=d140101019e3a, content=不错，认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa82827709, createdName=lj1770254679, createdTime=Sun Aug 22 02:00:35 CST 2021, time=2021-08-22, status=1, ipAttribution=)]
    2022-01-04 ms7000001100972409

    学习后获益匪浅

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1180624, encodeId=1a10118062486, content=学习后获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d945605913, createdName=ms7000001100972409, createdTime=Tue Jan 04 23:01:47 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077673, encodeId=57b910e7673f6, content=不错，认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7295648313, createdName=ms6000001488748724, createdTime=Tue Dec 07 10:01:01 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058031, encodeId=f272105803181, content=很方便, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ace5622459, createdName=ms3000001281480633, createdTime=Wed Oct 06 08:17:07 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011063, encodeId=a22210110634a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b594200092, createdName=13d7108bm77暂无昵称, createdTime=Tue Aug 24 18:05:51 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010197, encodeId=d140101019e3a, content=不错，认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa82827709, createdName=lj1770254679, createdTime=Sun Aug 22 02:00:35 CST 2021, time=2021-08-22, status=1, ipAttribution=)]
    2021-12-07 ms6000001488748724

    不错，认真学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1180624, encodeId=1a10118062486, content=学习后获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d945605913, createdName=ms7000001100972409, createdTime=Tue Jan 04 23:01:47 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077673, encodeId=57b910e7673f6, content=不错，认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7295648313, createdName=ms6000001488748724, createdTime=Tue Dec 07 10:01:01 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058031, encodeId=f272105803181, content=很方便, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ace5622459, createdName=ms3000001281480633, createdTime=Wed Oct 06 08:17:07 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011063, encodeId=a22210110634a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b594200092, createdName=13d7108bm77暂无昵称, createdTime=Tue Aug 24 18:05:51 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010197, encodeId=d140101019e3a, content=不错，认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa82827709, createdName=lj1770254679, createdTime=Sun Aug 22 02:00:35 CST 2021, time=2021-08-22, status=1, ipAttribution=)]
    2021-10-06 ms3000001281480633

    很方便

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1180624, encodeId=1a10118062486, content=学习后获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d945605913, createdName=ms7000001100972409, createdTime=Tue Jan 04 23:01:47 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077673, encodeId=57b910e7673f6, content=不错，认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7295648313, createdName=ms6000001488748724, createdTime=Tue Dec 07 10:01:01 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058031, encodeId=f272105803181, content=很方便, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ace5622459, createdName=ms3000001281480633, createdTime=Wed Oct 06 08:17:07 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011063, encodeId=a22210110634a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b594200092, createdName=13d7108bm77暂无昵称, createdTime=Tue Aug 24 18:05:51 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010197, encodeId=d140101019e3a, content=不错，认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa82827709, createdName=lj1770254679, createdTime=Sun Aug 22 02:00:35 CST 2021, time=2021-08-22, status=1, ipAttribution=)]
    2021-08-24 13d7108bm77暂无昵称

    好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1180624, encodeId=1a10118062486, content=学习后获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d945605913, createdName=ms7000001100972409, createdTime=Tue Jan 04 23:01:47 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077673, encodeId=57b910e7673f6, content=不错，认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7295648313, createdName=ms6000001488748724, createdTime=Tue Dec 07 10:01:01 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058031, encodeId=f272105803181, content=很方便, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ace5622459, createdName=ms3000001281480633, createdTime=Wed Oct 06 08:17:07 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011063, encodeId=a22210110634a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b594200092, createdName=13d7108bm77暂无昵称, createdTime=Tue Aug 24 18:05:51 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010197, encodeId=d140101019e3a, content=不错，认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa82827709, createdName=lj1770254679, createdTime=Sun Aug 22 02:00:35 CST 2021, time=2021-08-22, status=1, ipAttribution=)]
    2021-08-22 lj1770254679

    不错，认真学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2018 临床实践指南：急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗

国外神经外科相关专家小组（统称） · 2018-12-18

阿司匹林在动脉粥样硬化性心血管疾病中的临床应用：中国专家共识（2016）

中华医学会老年医学分会 · 2017-01-30

2015 阿司匹林用于心血管疾病一级预防的专家建议

中国心血管病相关专家小组（统称） · 2015-09-15

2016 USPSTF建议声明：阿司匹林用于心血管疾病和结直肠癌的一级预防

美国预防医学工作组(USPSTF,U.S. Preventive Services Task Force) · 2016-04-12

2014 USPSTF 小剂量阿司匹林预防孕妇先兆子痫建议声明

美国预防医学工作组(USPSTF,U.S. Preventive Services Task Force) · 2014-09-09

2014 ESC 立场声明：心血管疾病一级预防应用阿司匹林治疗

欧洲心脏病学会(ESC,European Society of Cardiology) · 2014-07-22